Reduced Corporate Capital Investment Due to Economic Slowdown
First written in FY2024-Q1. 5 of 8 entries say "Worsened", first in FY2024-Q3. Latest entry: FY2026.
PHC Holdings moved to the "Worse" side of this theme in 2024, 5 years after the typical company in this theme (2019).
The whole theme swung hardest in 2019: 41 of 56 companies on the "Worse" side.
17 other companies' latest entry also says "Worsened".
- FY2026WorsenedAnnual report
「The Biomedica business posted lower revenue as demand showed signs of recovery in Europe, Japan and elsewhere, but declined in the United States due to policy-related reductions in demand and other factors. Demand from US government agencies, universities and research institutions has continued to stagnate due to budget cuts and other factors.」
Demand stagnation due to budget cuts by US government agencies, universities and research institutions continued for the full fiscal year and emerged as a factor behind lower revenue in the Biomedica business. - 2026-05-13OtherEarnings
「In the U.S. market, signs of a recovery in demand are beginning to emerge, including the acquisition of large projects, particularly for pharmaceutical and biopharmaceutical companies. However, demand from U.S. government agencies, universities, and research institutions remains stagnant due to budget cuts and other factors.」
The U.S. market showed signs of recovery through the acquisition of large projects, while stagnant demand from government agencies, universities, and research institutions continued. - FY2026-H1WorsenedAnnual report
「In the Americas, demand stagnation due to budget cuts by US government agencies, universities and research institutions has continued, while delays have occurred frequently in biopharmaceutical-related projects and small and medium-sized projects.」
In the Americas, demand stagnation due to budget cuts by government agencies, universities and other institutions continued, and delays also occurred in biopharmaceutical-related projects and small and medium-sized projects. - FY2025WorsenedAnnual report
「The Biomedica business posted lower revenue despite a favorable foreign exchange impact, as it was affected mainly by declining demand in Asia, including Japan and China. In the research and medical support equipment field, the decline in large-scale projects from pharmaceutical companies, particularly in Japan, was a major factor behind the revenue decline.」
In addition to the economic slowdown and restraint on capital investment, declining demand in Asia, including Japan and China, and a decline in large-scale projects from Japanese pharmaceutical companies emerged as factors behind lower full-year revenue. - FY2025-H1WorsenedAnnual report
「The Biomedica business posted lower revenue despite a favorable foreign exchange impact, as it was affected mainly by declining demand in Asia, including Japan and China. In the research and medical support equipment field, the decline in large-scale projects from pharmaceutical companies, particularly in Japan, was a major factor behind the revenue decline.」
Declining demand in Asia, including Japan and China, and a decline in large-scale projects from Japanese pharmaceutical companies have emerged as factors behind lower revenue in the Biomedica business. - FY2024RestatedAnnual report
「Although both the Americas and Europe benefited from winning new projects, among other factors, this was insufficient to offset the revenue decline caused by difficult market conditions.」
Although new projects were won, this was insufficient to offset the revenue decline in the Americas and Europe caused by restraint on capital investment and difficult market conditions. - FY2024-Q3WorsenedAnnual report
「The Americas benefited from winning new projects from pharmaceutical and biotech companies, among other factors, but this was insufficient to offset the revenue decline caused by difficult market conditions resulting from lower capital investment.」
Although the Americas won new projects, difficult market conditions caused by lower capital investment continued to be reflected in lower revenue. - FY2024-Q1First statedAnnual report
「In the Americas, revenue was affected by companies' restraint on capital investment due to the economic slowdown. In Europe, sales to pharmaceutical and biotech companies for general demand were strong, but revenue in both regions declined year on year because the special demand for ultra-low-temperature freezers contracted.」
Companies' restraint on capital investment amid the economic slowdown in the Americas affected regional sales in the diagnostics and life sciences business.